Zaidi Anum Saqib, Peterson Gregory M, Bereznicki Luke R E, Curtain Colin M, Salahudeen Mohammed S
School of Pharmacy and Pharmacology, College of Health and Medicine, University of Tasmania, Hobart, Australia.
School of Pharmacy and Pharmacology, College of Health and Medicine, University of Tasmania, Hobart, Australia Faculty of Health, University of Canberra, Canberra, ACT, Australia.
Ther Adv Drug Saf. 2022 Mar 11;13:20420986221080796. doi: 10.1177/20420986221080796. eCollection 2022.
Trends in the incidence of adverse drug reaction (ADR)-related hospitalizations have been studied in the general population, but not specifically in people with dementia. This study aimed to investigate trends in the incidence of ADR-related hospitalizations among people with dementia, and identify the most commonly implicated drugs and diagnoses in these admissions.
This study utilized the administrative data of all adults admitted to the four major public hospitals of Tasmania, Australia, with a primary or secondary diagnosis of dementia from July 2010 to December 2019. ADR-related hospitalizations were identified by using diagnosis-based and external cause codes. The Cochran-Armitage test was used to examine trends in the incidence of ADR-related hospitalizations.
Of the 7552 people with dementia admitted to the hospital at least once within the study period, 1775 (23.5%) experienced at least one ADR-related hospitalization. The estimated annual incidence of ADR-related hospitalizations increased 18% (1484-1760 per 100,000 population with dementia, for trend <0.05) from 2010 to 2019. For those ADR-related admissions with a drug code recorded, 19.3% were due to antithrombotics and 11.5% to antihypertensives. The most frequent ADR-related admission diagnoses were renal diseases (72.9%). Length of hospital stay and in-hospital mortality were both significantly greater for ADR-related, relative to non-ADR-related, admissions (median 7 5 days and 11% 6.7%, respectively; < 0.001).
The annual incidence of ADR-related hospitalizations in people with dementia increased between 2010 and 2019. Antithrombotics were the most commonly implicated drug class. The ADR-related hospitalizations were associated with increased length of stay and greater mortality.
.
This study aimed to investigate trends in hospitalizations associated with medication problems among people with dementia, and identify the most commonly implicated drugs and diagnoses in these admissions.
This study utilized the administrative data of all adults admitted to the four major public hospitals of Tasmania, Australia, with dementia from July 2010 to December 2019.
The annual incidence of hospitalizations associated with medication problems among people with dementia increased nearly 20% over 10 years. The length of hospital stay and in-hospital mortality were significantly greater for hospitalizations related to medication problems.
The incidence of hospitalizations associated with medication problems in people with dementia increased between 2010 and 2019.
已在普通人群中研究了药物不良反应（ADR）相关住院率的趋势，但未专门针对痴呆症患者进行研究。本研究旨在调查痴呆症患者中ADR相关住院率的趋势，并确定这些住院病例中最常涉及的药物和诊断。
本研究利用了2010年7月至2019年12月期间入住澳大利亚塔斯马尼亚州四家主要公立医院且初步诊断或二次诊断为痴呆症的所有成年人的管理数据。通过基于诊断和外部病因代码来识别ADR相关住院病例。使用 Cochr an-Armitage检验来检查ADR相关住院率的趋势。
在研究期间至少住院一次的7552名痴呆症患者中，1775人（23.5%）经历了至少一次ADR相关住院。从2010年到2019年，ADR相关住院的估计年发病率增加了18%（每10万痴呆症患者中从1484例增至1760例，趋势P<0.05）。对于记录有药物代码的那些ADR相关入院病例，19.3%是由于抗血栓药物，11.5%是由于抗高血压药物。最常见的ADR相关入院诊断是肾脏疾病（72.9%）。与非ADR相关入院相比，ADR相关入院的住院时间和住院死亡率均显著更高（中位数分别为7天对5天和11%对6.7%；P<0.001）。
2010年至2019年期间，痴呆症患者中ADR相关住院的年发病率有所增加。抗血栓药物是最常涉及的药物类别。ADR相关住院与住院时间延长和更高的死亡率相关。
本研究旨在调查痴呆症患者中与用药问题相关的住院趋势，并确定这些住院病例中最常涉及的药物和诊断。
本研究利用了2010年7月至2019年12月期间入住澳大利亚塔斯马尼亚州四家主要公立医院且患有痴呆症的所有成年人的管理数据。
痴呆症患者中与用药问题相关的住院年发病率在10年内增加了近20%。与用药问题相关的住院的住院时间和住院死亡率显著更高。
2010年至2019年期间，痴呆症患者中与用药问题相关的住院发病率有所增加。
